Iba Molecular North America Inc

Kolon TissueGene, based in Rockville, MD, is a biopharmaceutical company focused on developing advanced cell therapies aimed at treating orthopedic diseases and degenerative disorders, with a notable emphasis on osteoarthritis of the knee. Their key product, TG-C, is designed to alleviate pain, enhance function, and slow disease progression through allogeneic cell and gene therapy. With a commitment to addressing unmet medical needs, Kolon TissueGene leverages innovative technology to advance clinical-stage therapies. The company aims to reshape treatment approaches within the orthopedic field through its state-of-the-art research and development initiatives. Generated from the website

Integrated Bio Therapeutics (IBT) is dedicated to the development of innovative vaccines and treatments for emerging infectious diseases. Their team of researchers and managers are at the forefront of cutting-edge research in the field. Stay informed with the latest updates from IBT through their news publications, and learn more about their groundbreaking work in the fight against infectious diseases. Generated from their website's infomation

GlycoMimetics develops novel small molecule therapeutics based upon the roles that carbohydrates play in biological processes. The company believes that carbohydrate mimics, or glycomimetic compounds, represent a new class of drugs. It has identified some compounds with potential therapeutic utility. One class has potential in the treatment of infectious diseases with a novel mechanism of action; the second is a class of anti-inflammatory compounds that have been shown to reduce key measures of inflammation. One of GMI s lead opportunities is to treat or prevent infections caused by Pseudomonas aeruginosa. Its objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections that have failed to respond to antibiotic treatment. The company also has compounds that inhibit selectin binding. Its initial focus in this program is to develop a product to treat acute exacerbations of asthma and chronic obstructive pulmonary disease. GlycoMimetics is headquartered in Gaithersburg, Md.